Lundbeck Moved US Headquarters to Massachusetts

The neuroscience firm is relocating its US base to Greater Boston to access local research institutions.

Updated on Sept. 25, 2026 in Alzheimer’s

Lundbeck Moved US Headquarters to Massachusetts

Live Poll

Do you believe moving corporate headquarters to major industry hubs improves long-term business performance?

Lundbeck has announced it will shift its US headquarters from Deerfield, Illinois, to Greater Boston, Massachusetts, over the next year. This move includes the establishment of a new global innovation hub to support the company's neuroscience initiatives.

Why it matters

The relocation aims to bolster the company's Focused Innovator strategy by positioning its research operations closer to prominent academic and healthcare institutions. This strategic shift is designed to expand innovation capacity and support long-term growth in neuroscience.

Lundbeck currently employs over 5,000 staff globally and brings 70 years of experience in neuroscience to its new Greater Boston innovation hub. The expansion is intended to scale its existing portfolio, though specific growth targets for its local US team remain under development.

The players

Lundbeck

A global pharmaceutical company focused on the research, development, and commercialization of neuroscience therapies for brain diseases.

The details

The transition involves relocating US executive and operational functions from Deerfield to Greater Boston, where the company already maintains a presence in Cambridge. By centralizing operations near regional research centers, Lundbeck aims to accelerate collaboration with academic and healthcare institutions. The company will retain its existing US team throughout the transition period.

September 25, 2026: Lundbeck announced the headquarters relocation.
Over the next year: The transition period for moving operations from Illinois to Massachusetts.

Health Landscape

This move reflects a broader trend of pharmaceutical firms centralizing research operations within the Greater Boston life sciences cluster to access deep scientific talent. It marks a shift from legacy corporate sites toward hubs that integrate directly with academic and medical institutions.

The company's increased focus on local innovation may impact the availability of future clinical trials and neuroscience research programs in the region. Patients interested in how such corporate shifts affect local access to upcoming treatment developments should discuss these changes with their physicians.

The takeaway

Lundbeck's shift to Massachusetts is a strategic move to integrate more deeply with regional research networks. Residents tracking advancements in neuroscience care should keep an eye on how these local collaborations influence the development of new treatments for brain-related conditions.